Pharma Company Gets $2.7M Grant to Continue 'Positive' Alzheimer's Treatment Trials

Neurotrope announced that its latest trial of Bryostatin-1, a treatment for Alzheimer's, showed positive results and that the company received a $2.7 million grant from the U.S. National Institute of Health to support another study, reports Fox Business . "I am encouraged by the NIH funding," said Cleveland Clinic Lou Ruvo Center for Brain Health Director Marwan Sabbagh. "The data suggests that Bryostatin may still be considered a new approach to Alzheimer's treatment." Neurotrope noted it also is studying Bryostatin for Fragile X syndrome, multiple sclerosis, stroke, traumatic brain injury, and other maladies.